Bank of America
ANIP icon

Bank of America’s ANI Pharmaceuticals ANIP Stock Holding History

Bank of America’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-128
Closed -$1K – 7861
2013
Q3 		$1K Buy
+128
New +$922 ﹤0.01% 7713

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of America's ANIP Position: Q1 2026 in Review

Bank of America increased its ANI Pharmaceuticals (ANIP) stake by 229% in Q1 2026, buying an estimated $8.18M and bringing the position to 150,532 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2829.

Bank of America first reported a position in ANIP in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.1M in Q2 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Bank of America held 150,532 shares of ANI Pharmaceuticals worth $11.6M as of Q1 2026.
  • Bank of America bought 104,828 ANI Pharmaceuticals shares in Q1 2026, an estimated $8.18M.
  • ANI Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2829 holding.
  • Bank of America first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's ANI Pharmaceuticals position peaked at $12.1M in Q2 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.